Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
NovoCure Limited NVCR
$73.97
+$0.8 (1.08%)
На 18:00, 12 мая 2023
+84.53%
Потенциал через год
Ранг: 2
Ключевые показатели
-
Marketcap
7845658830.00000000
-
week52high
120.03
-
week52low
56.06
-
Revenue
537840000
-
P/E TTM
-77
-
Beta
0.80415200
-
EPS
-0.87000000
-
Last Dividend
0.00000000
-
Next Earnings Date
04 мая 2023 г. в 12:00
Описание компании
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optune Lua for the treatment of malignant pleural mesothelioma. The company also has ongoing or completed clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Saint Helier, Jersey.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Truist Securities | Buy | Buy | 29 июл 2022 г. |
| Evercore ISI Group | Underperform | In-Line | 05 июл 2022 г. |
| HC Wainwright & Co. | Buy | 16 мая 2022 г. | |
| Piper Sandler | Overweight | Overweight | 13 мая 2022 г. |
| Loop Capital | Buy | 08 февр 2022 г. | |
| Wells Fargo | Equal-Weight | Equal-Weight | 28 окт 2022 г. |
| Truist Securities | Buy | Buy | 28 окт 2022 г. |
| HC Wainwright & Co. | Buy | Buy | 28 окт 2022 г. |
| Piper Sandler | Neutral | Overweight | 24 окт 2022 г. |
| Wells Fargo | Overweight | Equal-Weight | 29 ноя 2022 г. |
| Wells Fargo | Equal-Weight | Overweight | 06 янв 2023 г. |
| JP Morgan | Neutral | Neutral | 06 янв 2023 г. |
| Piper Sandler | Neutral | Neutral | 17 янв 2023 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Ben Arye Barak | A | 17152 | 150 | 06 янв 2023 г. |
| Burke William Patrick | A | 55594 | 108 | 06 янв 2023 г. |
| Benaim Ely | A | 28770 | 98 | 06 янв 2023 г. |
| GROENHUYSEN WILHELMUS CM | A | 165126 | 102 | 06 янв 2023 г. |
| Cordova Ashley | A | 74442 | 66 | 06 янв 2023 г. |
| Danziger Asaf | A | 13622 | 39 | 06 янв 2023 г. |
| Weinberg Uri | D | 1946 | 1946 | 05 янв 2023 г. |
| Weinberg Uri | D | 43286 | 1201 | 05 янв 2023 г. |
| Weinberg Uri | D | 44487 | 2617 | 05 янв 2023 г. |
| Weinberg Uri | A | 49050 | 1946 | 05 янв 2023 г. |
Новостная лента
Should You Buy Novocure Stock Right Now?
The Motley Fool
05 мая 2023 г. в 05:51
The case against Novocure centers on its declining sales and uncertainty about expanding into new markets. The case for Novocure focuses on the company's huge prospects if its late-stage clinical studies go well.
The 3 Most Promising Healthcare Tech Stocks for April 2023
InvestorPlace
26 апр 2023 г. в 17:59
In discussing healthcare tech stocks, it pays to understand what healthcare technology is broadly. Healthcare technology, also known as HealthTech, refers to any technology developed to improve the healthcare system.
NovoCure: Pipeline Conversion Is Key
Seeking Alpha
27 мар 2023 г. в 05:22
NovoCure has seen strong growth over the past decade but is unable to post profits with large sums invested into the pipeline. After softer sales momentum, pipeline conversion to other cancer types is necessary to drive appeal.
2 Best Defensive Stocks to Buy in March
The Motley Fool
08 мар 2023 г. в 18:00
The central bank's plan to aggressively hike interest rates might trigger a sharp correction in U.S. stock markets. Axon Enterprise and NovoCure are two companies with economically insensitive business models, making them ideal safe-haven plays.
Why NovoCure Stock Is Falling Today
The Motley Fool
23 февр 2023 г. в 13:44
Investors were looking for a stronger Q4 from the cancer company.